Rebinyn
| Product Specs | Description |
|---|---|
| Manufacturer Name | Novo Nordisk |
| Description | REBINYN is a recombinant DNAderived coagulation Factor IX concentrate |
| Indications for Adults: | |
Control and Prevention of Bleeding Episodes | Yes |
Perioperative Management | Yes |
Routine Prophylaxis to Prevent or Reduce the Frequency of Bleeding Episodes | Yes |
| Indications for Children: | |
Control and Prevention of Bleeding Episodes | Yes |
Perioperative Management | Yes |
Routine Prophylaxis to Prevent or Reduce the Frequency of Bleeding Episodes | Yes |
| Contraindications Nutrient in Cell Culture | Do not use in patients who have known hypersensitivity to REBINYN or its components, including hamster proteins |
| Viral Safety Process | Chromatography, detergent treatment, nanofiltration |
| Product Half-Life | Children ≤6 years : 69.6 (15.8 hours) Children 7-12 years : 76.3 (25.5 hours) Adolescents 13-17 years : 89.4 (24.1 hours) Adults ≥18 years : 83.0 (22.5 hours) |
| Product Recovery Percentage Mean incremental recovery IR (IU/dL per IU/kg) | Children ≤6 years : 1.51 (7.31) Children 7-12 years : 1.59 (16.2) Adolescents 13-17 years : 1.96 (14.7) Adults ≥18 years : 2.34 (11.3) |
| Manufacturing Method | Recombinant DNA technology |
| Storage Requirements/Shelf Life |
|
| Nominal Vial Size & Diluent Volume | 500, 1000, 2000, or 3000 IU/4mL of histidine solution |